Chris Anzalone, Arrowhead Pharmaceuticals CEO
As an Amgen's PhIII cardio plan takes shape, Royalty Pharma snags a stake in future sales
A few days after Amgen charted a Phase III map for an up-and-coming cardio drug, the biotech behind its development has decided to cash out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
